Compare GTY & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | KOD |
|---|---|---|
| Founded | 1955 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 1998 | 2018 |
| Metric | GTY | KOD |
|---|---|---|
| Price | $36.09 | $42.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $32.60 | ★ $35.43 |
| AVG Volume (30 Days) | 533.0K | ★ 858.4K |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | ★ 8.00 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $221,727,000.00 | N/A |
| Revenue This Year | $9.39 | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $83.93 | ★ N/A |
| Revenue Growth | ★ 9.02 | N/A |
| 52 Week Low | $25.39 | $5.00 |
| 52 Week High | $36.12 | $47.84 |
| Indicator | GTY | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 73.33 | 61.43 |
| Support Level | $32.41 | $39.37 |
| Resistance Level | N/A | $46.72 |
| Average True Range (ATR) | 0.58 | 3.18 |
| MACD | 0.18 | 0.45 |
| Stochastic Oscillator | 87.54 | 81.37 |
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.